| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 8,610 | 4,790 | 10,560 | 9,900 | 5,000 |
| Sales Growth | +79.75% | -54.64% | +6.67% | +98.00% | -66.44% |
| Net Income | -43,270 | -33,110 | -257,230 | -42,310 | -26,080 |
| Net Income Growth | -30.69% | +87.13% | -507.97% | -62.23% | -303.72% |
Scilex Holding Company WT (SCLXW)
Scilex Holding Company WT (SCLXW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Scilex Holding Company is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Scilex Holding Company, formerly known as Vickers Vantage Corp. I, is based in PALO ALTO, Calif.
Fiscal Year End Date: 12/31